Related Experiment Video
Updated: May 20, 2026
06:35
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
HMGB-1 as a target for inflammation controlling
Jose A Nogueira-Machado1, Caroline M de Oliveira Volpe
1Núcleo de Pós Graduação e Pesquisa (NPGP), Hospital Santa Casa de Misericórdia de Belo Horizonte - Belo Horizonte-MG-Brazil. aunog.bh@terra.com.br
Summary
Recent patents offer novel strategies to control inflammation by targeting High Mobility Group Box-1 (HMGB-1). These methods aim to down-regulate HMGB-1
Area of Science:
- Immunology and Molecular Biology
- Biotechnology and Pharmaceutical Research
- Patent Law and Intellectual Property
Background:
- High Mobility Group Box-1 (HMGB-1), also known as amphoterin, is a key mediator in the pathogenesis of various inflammatory diseases.
- HMGB-1 signaling involves receptors like RAGE, TLR2, and TLR4, leading to NF-kappaB activation and pro-inflammatory responses.
- Dysregulation of HMGB-1 contributes to conditions such as sepsis, arthritis, cancer, autoimmune diseases, and diabetes.
Purpose of the Study:
- To evaluate recent patents focused on products and methods for down-regulating the pro-inflammatory actions of HMGB-1.
- To categorize and analyze different patented strategies for controlling HMGB-1 activity and its downstream inflammatory effects.
- To discuss the mechanisms, roles, and potential efficacy of these patented approaches in managing inflammation.
Main Methods:
- Systematic review and classification of patents related to HMGB-1 modulation.
- Categorization based on the mechanism of action: anti-HMGB-1 antibodies, inhibition of HMGB-1 release, competitive antagonism, RAGE-HMGB-1 signaling blockade, TLR-HMGB-1 signaling blockade, and other modulators.
- Discussion of the scientific principles and therapeutic potential of each patent group.
Main Results:
- Patents are grouped into six categories based on their distinct strategies to control HMGB-1.
- These strategies include direct neutralization, inhibition of release, receptor antagonism, and modulation of signaling pathways.
- The evaluated patents represent diverse approaches to target HMGB-1 for therapeutic benefit in inflammatory conditions.
Conclusions:
- Numerous patented technologies aim to mitigate HMGB-1-driven inflammation through various mechanisms.
- These patented approaches offer potential therapeutic avenues for a range of inflammatory and related diseases.
- Further discussion on the efficacy and clinical translation of these patented strategies is warranted.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:26Gastritis II: Pathophysiology
The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:15G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...